Theravance Bio Ord TBPH

$17.03 0.00 (—)

Valuation

Market cap
884,181,000
Revenue TTM
$107,460,000
Net income TTM
$105,900,000
PE ratio
0.00
Forward PE
10.92
Profit margin
98.55%
Debt to equity
0.00

Trading

Volume
10,043,399
Avg volume
807,250
Day's range
$17.02 – $17.07
Shares out
51,919,000
Stochastic %K
38%
Beta
0.25
Analysts
Hold
Price target
$17.33

Price

Company profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic...

Show more

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
650 808 6000
Website
https://www.theravance.com
Address
901 Gateway Boulevard, South San Francisco, United States

Latest news

Stocktwits

Tdorsey1776 Sep 24, 2:09 PM
$TBPH Merger closed, pocket those free CVRs and a nice little profit. GLTA
0 replies
TwongStocks Sep 21, 4:42 PM
$TBPH $ZYME Equity Corporate Actions Alert #2026 - 668 Information Regarding the Merger of Theravance Biopharma, Inc. (TBPH) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-668 At a special meeting held on September 18, 2026, the shareholders of Theravance Biopharma, Inc. (TBPH) approved a merger with Zymeworks Inc. $ZYME The merger is tentatively scheduled to close September 23, 2026. TBPH shareholders will receive $17.00 plus one (1) non-transferable Contingent Value Right (CVR) per share at closing.
0 replies
theoptionsplug Sep 18, 12:34 PM
🗳️Shareholders of Theravance Biopharma $TBPH will vote on the company's proposed acquisition by Zymeworks $ZYME. At the time of publication, $TBPH shares were trading at a slight premium to the agreed deal price, suggesting investors may be anticipating improved terms or another potential outcome.
0 replies
GoforProMIS Jul 20, 11:33 AM
$PMN Last but not least with the PMN310 Platform ProMIS als targeting: 6. Multiple System Atrophy (MSA) | Pharmaceutical revenue in 2026: approx. USD 45–157 million | Leading companies (market leaders): As with FTD, there is no single drug specifically approved for MSA. Revenues go almost exclusively to generics manufacturers for symptomatic treatment: Parkinson’s medications such as levodopa (for motor rigidity) and blood pressure medications such as midodrine or fludrocortisone (for severe orthostatic hypotension). Pipeline players: Smaller biotech companies (such as $ATHE Therapeutics or $TBPH Biopharma) are working on compounds aimed at halting disease progression.
1 replies
Tdorsey1776 Jul 13, 1:52 PM
$TBPH Free CVRs..... Theravance Biopharma shareholders will receive $17.00 in cash for each outstanding ordinary share of Theravance Biopharma. Theravance Biopharma shareholders will also receive a contingent value right entitling them to 80% of net proceeds realized from any future license, divestiture or other monetization transaction involving ampreloxetine over the next ten years, with the remaining 20% to Zymeworks. In addition, if a license, divestiture or monetization transaction involving ampreloxetine is not executed by the closing, a designee from Theravance Biopharma will explore potential opportunities to license, divest or otherwise monetize ampreloxetine on behalf of Zymeworks for 12-months following closing.
3 replies
Mikelonggggggggg Jun 30, 6:00 PM
$ZYME $TBPH
1 replies
DeeB369 Jun 30, 2:08 PM
$NVAX Hi Guys, does anyone here trade these companies $ABEO and $TBPH......
1 replies
MikeyMcDermott Jun 29, 9:27 PM
$TBPH what is this scummy deal for no premium and a CVR. PSA: $SPRO MUST GET 100% OF CASH UPFRONT FOR TEBI RIGHTS
0 replies